Date	Period	Revenue/Estimate	Earnings Call
Nov 5, 2024	2025/Q2	16.019B / 16.030B	--
Aug 5, 2024	2025/Q1	16.352B / 16.420B	--
May 10, 2024	2024/Q4	14.019B / 14.176B	--
Feb 5, 2024	2024/Q3	17.176B / 17.430B	--
Nov 6, 2023	2024/Q2	15.625B / 15.677B	--

DatePeriodRevenue/EstimateEarnings Call

Nov 5, 20242025/Q216.019B / 16.030B--

Aug 5, 20242025/Q116.352B / 16.420B--

May 10, 20242024/Q414.019B / 14.176B--

Feb 5, 20242024/Q317.176B / 17.430B--

Nov 6, 20232024/Q215.625B / 15.677B--

Unlock Free Earnings Estimates

Open Account

ASKA Pharmaceutical Holdings Earnings Reports

ASKA Pharmaceutical Holdings: Confirmation letter

Nov 8, 2024 01:04 ET

ASKA Pharmaceutical Holdings: Half-Year Report - Term 4 (2024/04/01 - 2025/03/31)

Nov 8, 2024 01:02 ET

ASKA Pharmaceutical Holdings: Supplementary material for the 2nd quarter financial results summary for the fiscal year ending March 31, 2025

Nov 5, 2024 01:30 ET

ASKA Pharmaceutical Holdings: Summary of financial results for the 2nd quarter (interim period) for the fiscal year ending March 31, 2025 [Japanese GAAP] (consolidated)

Nov 5, 2024 01:30 ET

Symbol Price % Chg